What happened
Kbio Labs reported consolidated results for FY2025: revenue of US$61M (+14.1% year on year), operating profit of US$1.25M (+125.3% year on year) and a net loss of US$2.49M.
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$61M |
|---|---|
| Revenue vs a year earlier | +14.1% |
| Operating profit | US$1.25M |
| Net income | −US$2.49M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-27, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260227902005 → open original filing |
Source: DART. Information only, not investment advice.